Therapeutic strategies based on GLP-1 pathways

Advanced Studies in Medicine

Volumn 5, Issue 10 E, 2005, Pages

  Drucker, Daniel J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUGON; CJC 1131; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; RECOMBINANT PROTEIN; SULFONYLUREA DERIVATIVE; SYR 106124; TP 8211; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CONFERENCE PAPER; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE;

EID: 33645967809     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology. 2003;144:5145-5148.
2. Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205-211.
3. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-744.
4. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucogon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-830.
5. Doyle ME, McConville P, Theodorakis MJ, et al. In vivo biological activity of exendin (1-30). Endocrine. 2005;27:1-10.
6. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
7. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
8. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
9. Bregenholt S, Moldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun. 2005;330:577-584.
10. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003;52:1786-1791.
11. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335-1342.
12. Matthews D, Madsbad S, Schmitz O, et al. The long-acting GLP-1 derivative, NN2211, a new agent for the treatment of type 2 diabetes [abstract]. Diabetes. 2002;51:A84.
13. Guivarch PH. 18th International Diabetes Federation Congress; Paris, France; August 24-29, 2003.
14. Baggio LL, Huang O, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004;53:2492-2500.
15. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA. 2000;97:6874-6879.
16. Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes. 2004;53:1326-1335.
17. Ahren B, Landin-Olsson M, Jansson PA, et al. The DPPIV inhibitor, LAF237, reduces fasting and postprandial glucose in subjects with type 2 diabetes over a 4 week period by increasing active GLP-1, sustaining insulin and reducing glucagon [abstract]. Diabetes. 2003;52(suppl 1):A15.